Partner Steve Maebius contributed an article to Pharmaceutical Executive, “New Challenge to IP Innovation,” on August 31, 2016. The article provided an overview of the use of Inter Partes Reviews (IPRs) in the pharmaceutical industry, for both generic and originator companies. Maebius discussed the findings of a survey that analyzed 111 IPR filings by generic drug companies against pharmaceutical patents and highlighted key considerations for originator companies.
Author(s)
Related Insights
July 23, 2025
Events
Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact
Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in Strafford’s upcoming webinar titled “Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact” on July 23.
September 30, 2025
Events
FDA Regulation of AI-Enabled Medical Devices
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking at the American Bar Association Health Law Section’s Healthcare Delivery & Innovation Conference on September 30.
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…